Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 2004, p. 775-779, Vol. 11, No. 4
1071-412X/04/$08.00+0 DOI: 10.1128/CDLI.11.4.775-779.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Use of a Novel Enzyme Immunoassay Based on Detection of Circulating Antigen in Serum for Diagnosis of Helicobacter pylori Infection
Abdelfattah M. Attallah,1* Hisham Ismail,1 Gellan G. Ibrahim,1 Mohamed Abdel-Raouf,2 Ahmed M. El-Waseef,1,3 and Mohamed Abdel-Wahab2
Research & Development Department, Biotechnology Research Center, New Damietta,1
Gastro-Enterology Center, and,2
Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt3
Received 27 July 2003/
Returned for modification 20 January 2004/
Accepted 15 March 2004

ABSTRACT
Recently,
noninvasive diagnostic tests for
Helicobacter pylori infection
have gained in significance. We have developed a sensitive
and specific
noninvasive immunoassay based on the detection
of an
H. pylori
circulating antigen (HpCA) in sera from
H. pylori-infected
individuals.
Monospecific antibody and Western blot analyses were used
to
demonstrate the presence of the target antigen in
H. pylori
cell
lysate and serum samples. A novel enzyme-linked immunosorbent
assay
(ELISA) was developed for the detection of HpCA in serum.
Endoscopic
biopsy specimens from the gastric antra of 221 individuals
(143
males and 78 females) with dyspeptic symptoms were evaluated
for
H. pylori infection, with culture used as a "gold
standard"
for diagnosis. The target
H. pylori antigen
was identified at
58 kDa. HpCA has been detected by ELISA with high
degrees of
sensitivity, specificity, and efficiency
(>90%), and ELISA
results show no significant difference
(
P > 0.05) from results
of
H. pylori culture
of gastric biopsy specimens. The test's
positive and negative
predictive values were also high (95 and
86%, respectively). In
conclusion, a sensitive and specific
immunoassay was developed for the
detection of HpCA in human
serum. This test can be applied for
noninvasive laboratory and
field diagnoses of
H. pylori
infection.

INTRODUCTION
Helicobacter pylori is a common bacterial infection in humans
that
is responsible for a variety of gastroduodenal
pathologies,
peptic and gastric ulcers, mucosa-associated lymphoid
tissue
lymphoma, and gastric carcinoma
(
7,
7a,
14,
25). Several tests
can be
used to diagnose
H. pylori infection; the selection of
the
appropriate test depends on the clinical setting
(
12,
18).
H. pylori
infection can be diagnosed by tests requiring upper
gastrointestinal
endoscopy for the retrieval of a gastric biopsy
specimen
(microbiological culture, histological examination,
and rapid urease
tests). These methods have high sensitivities
and specificities
(
10), yet the
invasiveness and expense of
direct observation of the organism have led
to a search for
valid and reliable noninvasive alternatives
(
33). During recent
years,
noninvasive diagnostic tests for
H. pylori infection
have gained
in significance
(
29). Although PCR, a
powerful method known
for its high sensitivity, can detect low numbers
of
H. pylori and has been used to follow up eradication
therapy, PCR requires
specialized laboratory facilities and is not
generally available
as a routine diagnostic test
(
13). The
urea breath test has
been the most widely used accurate
noninvasive test, both in
the pretreatment examination of infected
individuals and for
early-posttreatment follow-up, and meets the
requirements for
such a test
(
9). However, the
performance of the test has been
associated with some disadvantages.
Although it is less costly
than endoscopy, the urea breath test
requires a specialized
technician and expensive instrumentation that is
not available
in routine clinical laboratories (a scintillation counter
or
a mass spectrometer) for analyzing and handling the radioactive
isotope
in a specific way; also, patients may be hesitant to ingest
radioactive
test material
(
31). Enzyme immunoassays
have been used to detect
H. pylori infection in human
secretions, such as feces, urine,
and saliva
(
14). Such assays are
attractive in comparison with
other noninvasive methods because they
are simple, inexpensive,
and less of a burden for the patient
(
1,
15). Here, we have
identified
an
H. pylori antigen in the sera from infected
individuals and
described the development of an antigen detection
enzyme-linked
immunosorbent assay (ELISA) suitable for the laboratory
diagnosis
of and the screening of large populations for
H.
pylori infection.

MATERIALS AND METHODS
Clinical specimens.
A total of 221 individual serum
samples were collected in the
Gastro-Enterology and Surgery Center,
Mansoura University, Mansoura,
Egypt. The individuals were 143 males
aged 14 to 74 years (mean,
40.83 ± 11.72 years; median, 42
years) and 78 females
aged 16 to 75 years (mean, 41.69 ± 13.81
years; median,
39.5 years). All sera were stored at
20°C until used.
All patients underwent upper
gastroduodenal endoscopy, and multiple
gastric biopsy specimens were
taken from the antrum and then
processed for microbiological culture of
H. pylori. The endoscopy
showed 69 gastritis cases
(31.2%), 21 gastric erosion cases
(9.5%), 8 gastric ulcer
cases (3.6%), 17 duodenitis cases (7.7%),
4 duodenal
erosion cases (1.8%), 32 duodenal ulcer cases (14.5%),
and
70 normal endoscopic mucosa cases (31.7%). The Ethical
Committee
of the Gastro-Enterology and Surgery Center, Mansoura
University,
approved the present study. Informedconsent was obtained
from
all participants, and they were fully informed of the diagnostic
procedures
involved and nature of the disease. Most of these subjects
had
received no antimicrobial therapies during the previous 3
months.
Microbiological culture.
H. pylori
was cultured by rubbing the gastric biopsy specimens of Egyptian
patients onto Columbia agar plates supplemented with lysed horse blood
(5%) and Skirrow's supplement containing vancomycin,
trimethoprim lactate, cefsulodin, and amphotericin B (Oxoid,
Basingstoke, United Kingdom). Agar plates were incubated at
37°C for 4 to 7 days in a microaerophilic atmosphere (5%
O2, 10% CO2, 85% N2, and
99% relative humidity) provided by a CO2 incubator
(Heraeus Instruments, Berlin, Germany). The microorganism
was identified as H. pylori by the standard methods, on the
basis of colony morphology, Gram staining, and the production of
urease, catalase, and oxidase enzymes
(11).
Preparation of H. pylori cell lysate.
Bacterial cells were
harvested, washed three times in phosphate-buffered saline (PBS; pH
7.2), and disrupted by sonication three times at 4°C for
15 s each time at 47 kHz with a Bransonic ultracleaner
(B-1200 E-1; Branson Ultrasonic Corporation, Danbury, Conn.). After
centrifugation at 10,000 rpm (J2-HS; Beckman Instruments,
Inc., Fullerton, Calif.) for 10 min at 4°C, the protein content
of the supernatant solution was determined with the use of bovine serum
albumin as a standard
(17). The supernatant was
split into aliquots and stored at 20°C until
used.
Production of anti-H. pylori antibody.
A
group of three New Zealand rabbits were immunized subcutaneously at
three different inoculation sites with 500 µg of H.
pylori cell lysate diluted (by volume) with Freund's complete
adjuvant. Another group of three New Zealand rabbits were immunized
with 500 µg of the purified 58-kDa H. pylori antigen
diluted (by volume) with Freund's complete adjuvant. On day 15,
the rabbits were immunized again with the same dose of antigen
emulsified with incomplete Freund's adjuvant. On day 28, rabbits
were immunized with one more dose of antigen with incomplete adjuvant,
and they were sacrificed 4 days later. Blood samples were collected
from all rabbits on day 0 and at 28 and 32 days after immunization, and
sera were separated. The reactivity of the collected sera was tested
against serial concentrations of H. pylori lysate and the
purified 58-kDa antigen by using an indirect ELISA and anti-rabbit
immunoglobulin G (IgG) alkaline phosphatase conjugate (Sigma).
Incubation with the enzyme substrate produced a color in proportion to
the amount of anti-H. pylori IgG antibodies
present.
SDS-PAGE and gel electroelution.
Various
samples (see Results) were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), at 50
µg/lane, using vertical slabs of 12 or 16%
polyacrylamide (16).
Molecular weight standards (Sigma) were run in parallel. After staining
with Coomassie blue R-250, the band of interest (58 kDa) was cut, and
the antigen was electroeluted from the polyacrylamide gel
(2). The protein content
of the electroeluted antigen was determined, and the samples were
stored at 20°C until used. Initially, the purity of
the electroeluted antigen was assessed using SDS-PAGE and Coomassie
blue staining. Then, serum samples (diluted 1:100 in 0.05 M Tris buffer
containing 200 mM NaCl and Tris-buffered saline [TBS; pH
7.4]) of 10 infected and 5 noninfected individuals, as proven by
microbiological culture, were used to confirm the immunogenicity of the
purified antigen by using anti-human IgG alkaline phosphatase conjugate
(Sigma) and Western blotting.
Western blots.
Samples separated by
SDS-PAGE (as described above) were electrotransferred onto a
nitrocellulose membrane (0.45-µm pore size; Sigma) in a protein
transfer unit (28). The
nitrocellulose filter was blocked by 5% (wt/vol) nonfat dry milk
dissolved in 0.05 M TBS (pH 7.4), rinsed in TBS, and incubated with
rabbit anti-H. pylori lysate antibodies or anti-58-kDa-antigen
antibodies diluted in blocking buffer with constant shaking. The blots
were then washed, followed by incubation for 2 h with goat
anti-rabbit IgG alkaline phosphatase conjugate (Sigma) diluted 1:350 in
TBS. After being washed, the blots were soaked in substrate (premixed
5-bromo-4-chloro-3-indolylphosphate [BCIP] and Nitro Blue
Tetrazolium in 0.1 M Tris buffer, pH 9.6 [ABC Diagnostics, New
Damietta, Egypt]). The color reaction was observed within 10 min,
and dipping the blots in distilled water then stopped the
reaction.
ELISA for H. pylori circulating antigen (HpCA) in serum.
After optimization of
ELISA conditions, each well of polystyrene microtiter plates was coated
with 50 µl of a tested human serum sample diluted in
carbonate-bicarbonate buffer (pH 9.6). The plates were incubated
overnight at room temperature and washed three times with 0.05%
(vol/vol) PBS-T20 (pH 7.2), and then free active sites were blocked
with 0.2% (wt/vol) nonfat milk in carbonate-bicarbonate buffer.
After washing of the plates, 50 µl of the specific
antisera/well was added to the 58-kDa antigen diluted 1:100 in PBS-T20,
and the mixture was incubated at 37°C for 2 h. After
the plates were washed, 50 µl of anti-rabbit IgG alkaline
phosphatase conjugate (Sigma)/well diluted in 0.2% (wt/vol)
nonfat milk in PBS-T20 was added, and the mixture was incubated at
37°C for 1 h. The amount of coupled conjugate was
determined by incubation with 50 µl of p-nitrophenyl
phosphate substrate (Sigma)/well for 30 min at 37°C. The
reaction was stopped by using 3 M NaOH, and absorbance was read at 405
nm. The cutoff level of the ELISA, above or below which the tested
sample is considered positive or negative, was calculated as the mean
ELISA optical densities (range, 0.135 to 0.377) of a group of 24 serum
samples from noninfected healthy individuals ± 3 standard
deviations [i.e., 0.257 ± (3 x 0.047) =
0.398]. The mean absorbance value of a group of 32 H.
pylori-positive individuals was 0.751 (range, 0.411 to
1.250).
Characterization of the purified H. pylori antigen.
To determine some of the target
antigen's chemical characteristics, samples of the antigen were
treated with protease and other chemical reagents and then tested by
ELISA to see if these treatments affected the active epitope as
described by Attallah et al.
(2). Lysate and bovine
serum albumin were tested in parallel, as positive and negative
controls, respectively.
Statistical analysis.
Standard methods
were used to calculate sensitivity, specificity, efficiency, and
positive and negative predictive values. All parameters were
transferred to an IBM PC-AT-compatible computer for analysis using
statistical analysis program package Instate Software for Science,
version 2.3 (Graphpad Software, Inc., San Diego, Calif.). The
Mann-Whitney U test was used to compare the means of two distributions.
Fisher's exact test was used to compare the differences between
two proportions. P values (two-tailed test) of <0.05
were considered
significant.

RESULTS
Reactivity of the developed anti-H. pylori antibodies.
Sera collected from the rabbits
immunized with the
H. pylori lysate reacted strongly with
several bands of various molecular
weights on Western blots. However, a
broad band at 58 kDa in
H. pylori lysate showed particularly
high reactivity. The 58-kDa
H. pylori antigen was isolated and
purified from
H. pylori lysate
by using a gel electroelution
technique. Antibodies specific
to the 58-kDa
H. pylori antigen
were produced in rabbits immunized
with the purified
H. pylori
antigen. In a Western blot, the
developed IgG antibodies appeared to
react only with an antigen
of 58 kDa in whole
H. pylori cell
lysate and purified antigen
(Fig.
1). Sera collected from these rabbits at zero time as
control sera were not
specifically reactive with that band (Fig.
1).
In addition, sera
collected from immunized rabbits showed increased
levels of specific
IgG antibodies (
P < 0.05) towards
H. pylori
lysate
and the purified antigen in comparison with levels in the
control
sera as determined by ELISA. No significant batch-to-batch
variation
(
P > 0.05) was shown by ELISA in the
reactivities of various
blood specimens from the various
rabbits.
Partial biochemical characteristics of the H. pylori antigen.
The purified
H. pylori antigen
was analyzed by SDS-PAGE and
was Coomassie blue stained at 58 kDa. The
reactivity of the
purified
H. pylori antigen by ELISA was lost
after treatment
with a solution containing 0.2 M HCl or 0.2
M NaOH or 180 mM
ß-mercaptoethanol and was maintained after
sodium
meta-periodate oxidation. Trichloroacetic acid
(40%)-precipitated
antigen showed high reactivity against the
specific anti-
H. pylori antibody, and the trichloroacetic acid
supernatant did
not show reactivity. Also, the antigen was treated with

-chymotrypsin
enzyme, and the enzymatic reactions were stopped
at different
time intervals. The reactivity of the
H. pylori
antigen was
decreased by increasing the incubation time of the enzyme
but
was completely lost after 20
min.
Identification of the H. pylori antigen in human serum by Western blot analysis.
Anti-H. pylori-monospecific
antibodies in Western blot analysis of serum samples from 24 H.
pylori-infected individuals recognized the 58-kDa band in the sera
of all infected patients. In addition, a possible degradation product
with a molecular mass of 42 kDa was identified in some of these serum
samples. No specific reaction was observed with the sera from eight
uninfected individuals as a control group. The detection of the H.
pylori target antigen in selected serum samples from infected and
noninfected individuals by Western blotting is shown in Fig.
2.
Detection of the 58-kDa HpCA in human serum by ELISA.
A novel ELISA
based on the detection of the target HpCA in serum
was developed for
the diagnosis of
H. pylori infection. The
mean absorbance
values of the serum samples were 0.751 (range,
0.411 to 1.250; all
positive) for 32
H. pylori-positive subjects
and 0.271 (range,
0.135 to 0.377; all negative) for 24
H. pylori-negative
subjects
(
P < 0.001, Mann-Whitney U test). To evaluate
the clinical
application of the test, endoscopic biopsy specimens from
the
gastric antra of 221 individuals were evaluated for
H.
pylori infection by using culture as the gold standard for
diagnosis.
A total of 144 individuals were diagnosed as
H.
pylori infected
and 77 were diagnosed as noninfected by
microbiological culture.
No significant differences (
P
> 0.05, Fisher's exact test)
were shown between the
results of circulating-antigen detection
by ELISA and
H.
pylori culture of gastric biopsy samples. The
sensitivity,
specificity, efficiency, and predictive values
of positive and a
negative results for the newly developed ELISA
in comparison to those
of microbiological culture are shown
in Table
1.
View this table:
[in this window]
[in a new window]
|
TABLE 1. ELISA
detection of a 58-kDa HpCA in 221 serum samples of individuals who were
confirmed by culture to be infected or not infected with H.
pylori
|

DISCUSSION
Immunodiagnosis of
H.
pylori infection is attractive in comparison
with other
noninvasive diagnostic methods for the investigation
of upper
gastrointestinal symptoms. There are a number of different
techniques
for antibody detection
(
19,
30). However, antibody
detection
tests are less useful in children aged below 10
(
21) and are
not suitable
for the follow-up examination of treated patients
(
15,
22).
In addition, the
accuracy of these tests is no longer adequate
to justify their clinical
use on clinical or economic grounds
(
29).
The H.
pylori stool antigen enzyme immunoassay has been validated in
various regions of the world with comparable sensitivities and
specificities (13,
31). However, a potential
problem with the H. pylori stool antigen test appears to be
patient reluctance about stool handling, and this could prove to be a
significant obstacle in patient compliance and the acceptability of the
test in everyday clinical practice
(5,
34). In addition, the
accumulating data concerning the use of the test in evaluating
treatment remain unconvincing
(24).
Soluble
bacterial antigens of H. pylori on the stomach mucosa can be
passively absorbed by pinocytosis and can be transferred into the blood
through injured tight junctions and by the absorption of intestinal
mucosal epithelial cells
(3,
4). In the present study,
we were able to detect a specific 58-kDa antigen in H. pylori
lysate and in serum samples from H. pylori-infected
individuals. The molecular mass of the serum antigen is analogous to
the 58-kDa fragment of the 87-kDa cytotoxin domain of the VacA protein
(8,
23,
27), the subunit cellular
antigen (59 kDa) of the native H. pylori catalase
(26), and the H.
pylori catalase gene product
(20). However, further
investigation of the structure of the target H. pylori serum
antigen will be performed.
Based on these encouraging results, we
have developed a direct ELISA based on the detection of HpCA in serum
samples and suitable for the laboratory diagnosis and screening of
large populations for H. pylori infection. The HpCA test has
several potential advantages over other techniques for population
studies. No expensive instrumentation or expertise is required to
perform a standard ELISA. The advantages of the HpCA test include its
ability to detect the presence of H. pylori and its usefulness
with individuals for whom endoscopy is difficult to justify
(8).
To evaluate the
diagnostic performance of the HpCA diagnostic test, we included in the
study 221 patients with dyspeptic symptoms who were examined by upper
gastrointestinal endoscopy. The infection with H. pylori was
judged to be present when a microbiological culture of gastric biopsy
specimens was positive. The HpCA test detected the circulating antigen
in 92% of sera from H. pylori-infected individuals,
with high specificity (91%) among noninfected
individuals.
The false-negative results (8%) of our HpCA
ELISA may be explained as follows. The H. pylori antigen level
among false-negative samples may be too low to be detected by the
present assay conditions. The direct ELISA, with which the
unknown elements are bound directly to the plate, may
suffer from problems with uneven absorption and interference with
absorption due to other serum components. Most commercial tests are of
the antigen capture variety, which requires an additional antibody;
however, with further work, the HpCA test can be improved. H.
pylori antigens have been found as components of circulating
immune complexes (34), so
it may be necessary to dissociate the immune complexes to achieve a
higher sensitivity in the immunoassay
(6).
The
false-positive results (9%) reported by the HpCA test may be due
to biopsy sampling errors as a result of the patchy nature of the
H. pylori infection, and additional biopsies from the corpus
are required (32). The
antigen detection method showed high efficiency (92%) and high
positive (95%) and negative (86%) predictive values. The
high positive predictive value of the HpCA test may enhance the
applicability of this test to children.
Although the present
study confirmed the sensitivity of the HpCA test in the diagnosis of
H. pylori infection, exploring its use in posttreatment
follow-up may have greater clinical implications, since endoscopy
becomes less justifiable. In conclusion, the newly developed
circulating antigen detection test, HpCA ELISA, is an alternative,
easy-to-use, noninvasive test for the detection of H. pylori
infection.

FOOTNOTES
* Corresponding author. Mailing address: Biotechnology Research Center, P.O. Box (14), New Damietta City, Egypt. Phone: (02) (057) (402889). Fax: (02) (057) (401889). E-mail:
amattallah{at}hotmail.com.


REFERENCES
1 - Archimandritis,
A., A. Giontzis, A. Smilakou, M. Tzivras, and P. Davaris.1999
. Diagnosis of Helicobacter pylori infection
by HpSA test. Lancet
354:1210-1211.[Medline]
2 - Attallah,
A. M., C. A. Abdel Malak, H. Ismail, A. El-Saggan,
M. Omran, and A. Tabll. 2003. Rapid and simple
detection of a Mycobacterium tuberculosis circulating antigen
in serum using dot-ELISA for field diagnosis of pulmonary tuberculosis.
J. Immunoass. Immunochem.
24(1):87-93.
3 - Cao,
P., M. S. McClain, M. H. Forsyth, and T.
L. Cover. 1998. Extracellular release of antigenic
proteins by Helicobacter pylori. Infect. Immun.
66:2984-2986.[Abstract/Free Full Text]
4 - Crabtree,
J. E. 1995. Immune and inflammatory response to
Helicobacter pylori infection. Scand. J.
Gastroenterol.
31(215):3-10.
5 - Cullen,
K. P., B. M. Broderick, J. Jayaram, B. Flynn, and
H. J. O'Connor. 2002. Evaluation of the
Helicobacter pylori stool antigen (HpSA) test in routine
clinical practiceis it patient-friendly? Ir. Med.
J.
95:305-306.[Medline]
6 - De
Jonge, N., Y. E. Fillie, and A. M. Deelder.1987
. A simple and rapid treatment (trichloroacetic acid
precipitation) of serum samples to prevent non-specific reactions in
the immunoassay of a proteoglycan. J. Immunol.
Methods
99:195-197.[CrossRef][Medline]
7 - Eck,
M., B. Schmausser, R. Haas, A. Greiner, S. Czub, and H.
Muller-Hermelink. 1997. MALT-type lymphoma of the
stomach is associated with Helicobacter pylori strains
expressing the CagA protein. Gastroenterology
112:1482-1486.[CrossRef][Medline]
7 - Forman,
D. 1998. Helicobacter pylori: the gastric
cancer problem. Gut
43:533-534.
8 - Garner, J. A., and
T. L. Cover. 1996. Binding and
internalization of the Helicobacter pylori vacuolating
cytotoxin by epithelial cells. Infect. Immun.
64:4197-4203.[Abstract]
9 - Gatta,
L., N. Vakil, C. Ricci, J. F. Osborn, A. Tampieri, F. Perna,
M. Miglioli, and D. Vaira. 2003. A rapid, low-dose,
13C-urea tablet for the detection of Helicobacter
pylori infection before and after treatment. Aliment.
Pharmacol. Ther.
17:793-798.[CrossRef][Medline]
10 - Graham,
D. Y., and W. A. Qureshi. 2001.
Markers of infection, p. 499-510.
In H. L. T. Mobley, G. L. Mendz,
and S. L. Hazell (ed.), Helicobacter pylori:
physiology and genetics. ASM Press, Washington,
D.C.
11 - Hachamkin,
I. 1995. Campylobacter and
Acrobacter, p. 483-491.
In P. R. Murray, E. J. Baron, M.
A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.),
Manual of clinical microbiology, 6th ed. ASM Press, Washington,
D.C.
12 - Howden,
C. W., and R. H. Hunt. 1998.
Guidelines for the management of Helicobacter pylori
infection. Am. J. Gastroenterol.
93:2330-2338.[Medline]
13 - Kabir,
S. 2001. Detection of Helicobacter pylori in
feces by culture, PCR, and enzyme immunoassay. J. Med.
Microbiol.
50:1021-1029.[Abstract/Free Full Text]
14 - Kabir,
S. 2003. Clinic-based testing for Helicobacter
pylori infection by enzyme immunoassay of faeces, urine and
saliva. Aliment. Pharmacol. Ther.
17:1345-1354.[CrossRef][Medline]
15 - Kokkola,
A., H. Rautelin, P. Puolakkainen, P. Sipponen, M. Farkkila, R.
Haapiainen, and T. U. Kosunen. 2000.
Diagnosis of H. pylori infection in patients with atrophic
gastritis: comparison of histology, 13C-urea breath test,
and serology. Scand. J. Gastroenterol.
35(2):138-141.[CrossRef][Medline]
16 - Laemmli,
U. K. 1970. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature
277:680-685.
17 - Lowry,
O. H., N. J. Rosebrough, A. L. Farr, and
R. J. Randall. 1951. Protein measurement
with Folin-phenol reagent. J. Biol. Chem.
193:265-275.[Free Full Text]
18 - Megraud,
F. 1997. How should Helicobacter pylori
infection be diagnosed? Gastroenterology
113:S93-S98.[Medline]
19 - Newell,
D., and A. Stacet. 1993. Serology, p.139
-148. In T. C.
Northfield, M. Mendall, and P. M. Goggin (ed.),
Helicobacter pylori infection. Kluwer Academic Publishers,
London, United
Kingdom.
20 - Odenbreit,
S., B. Wieland, and R. Haas. 1996. Cloning and genetic
characterization of Helicobacter pylori catalase and
construction of a catalase-deficient mutant strain. J.
Bacteriol.
178:6960-6967.[Abstract/Free Full Text]
21 - Okuda,
M., E. Miyashiro, M. Koike, T. Tanaka, M. Bouoka, S. Okuda, and N.
Yoshikawa. 2002. Serodiagnosis of Helicobacter
pylori infection is not accurate for children aged below 10.Pediatr. Int.
44:387-390.[CrossRef][Medline]
22 - Perez-Perez,
G. I., A. F. Cutler, and M. J.
Blaser. 1997. Value of serology as a noninvasive
method for evaluating the efficacy of treatment of Helicobacter
pylori infection. Clin. Infect. Dis.
25:1038-1043.[Medline]
23 - Reyrat,
J. M., S. Lanzavecchia, P. Lupetti, M. de Bernard, C.
Pagliaccia, V. Pelicic, M. Charrel, C. Ulivieri, N. Norais, X. Ji, V.
Cabiaux, E. Papini, R. Rappuoli, and J. L. Telford.1999
. 3D imaging of the 58 kDa cell binding subunit of the
Helicobacter pylori cytotoxin. J. Mol. Biol.
290:459-470.[CrossRef][Medline]
24 - Roth,
D. E., D. N. Taylor, R. H. Gilman, R.
Meza, U. Katz, C. Bautista, L. Cabrera, B. Velapatiño, C. Lebron,
M. Razúri, J. Watanabe, T. Monath, and the Gastrointestinal
Physiology Working Group. 2001. Posttreatment
follow-up of Helicobacter pylori infection using a stool
antigen immunoassay. Clin. Diagn. Lab. Immunol.
8:718-723.[Abstract/Free Full Text]
25 - Suerbaum,
S., and P. Michetti. 2002. Helicobacter
pylori infection. N. Engl. J.
Med.
347:1175-1186.[Free Full Text]
26 - Suzuki,
N., M. Wakasugi, S. Nakaya, N. Kokubo, M. Sato, H. Kajiyama, R.
Takahashi, H. Hirata, Y. Ezure, Y. Fukuda, and T. Shimoyama.2002
. Catalase, a specific antigen in the feces of human
subjects infected with Helicobacter pylori. Clin.
Diagn. Lab. Immunol.
9:784-788.[Abstract/Free Full Text]
27 - Telford,
J. L., P. Ghiara, M. Dell'Orco, M. Comanducci, D.
Burroni, M. Bugnoli, M. F. Tecce, S. Censini, A. Covacci, Z.
Xiang, et al. 1994. Gene structure of the
Helicobacter pylori cytotoxin and evidence of its key role in
gastric disease. J. Exp. Med.
179:1653-1658.[Abstract/Free Full Text]
28 - Towbin,
H., T. Staehelin, and J. Gordon. 1979. Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose sheets:
procedure and some applications. Proc. Natl. Acad. Sci.
USA
76:4350-4354.[Abstract/Free Full Text]
29 - Vaira,
D., and N. Vakil. 2001. Blood, urine, stool, breath,
money, and Helicobacter pylori. Gut
48:287-289.[Free Full Text]
30 - Vaira,
D., J. Holton, M. Menegatti, C. Ricci, F. Landi, A. Ali, L. Gatta, C.
Acciardi, S. Farinelli, M. Crosatti, S. Berardi, and M. Miglioli.1999
. New immunological assays for the diagnosis of
Helicobacter pylori infection. Gut
45(Suppl.
1):I23-I27.[Free Full Text]
31 - Vaira,
D., J. Holton, M. Menegatti, C. Ricci, L. Gatta, A. Geminiani, and M.
Miglioli. 2002. Invasive and non-invasive tests for
Helicobacter pylori infection. Aliment. Pharmacol.
Ther.
14(3):13-22.
32 - van
Zwet, A. A., J. C. Thijs, R. Roosendaal,
E. J. Kuipers, S. Pena, and J. de Graaff.1996
. Practical diagnosis of Helicobacter pylori
infection. Eur. J. Gastroenterol. Hepatol.
8:501-507.[Medline]
33 - Westblom,
T. U., and B. D. Bhatt. 1999.
Diagnosis of Helicobacter pylori infection. Curr. Top.
Microbiol. Immunol.
241:215-235.[Medline]
34 - Zhu,
Y., J. Lin, D. Li, Q. Du, K. Qian, Q. Wu, and S. Zheng.2002
. Helicobacter pylori antigen and its IgG,
IgA-type specific immunocomplexes in sera from patients with
Helicobacter pylori infection. Chin. Med. J.
115:381-383.[Medline]
Clinical and Diagnostic Laboratory Immunology, July 2004, p. 775-779, Vol. 11, No. 4
1071-412X/04/$08.00+0 DOI: 10.1128/CDLI.11.4.775-779.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.